Tesamorelin · research summary

Growth Hormone Releasing Hormone Reduces Circulating Markers of Immune Activation in Parallel with Effects on Hepatic Immune Pathways in Individuals with HIV-infection and Nonalcoholic Fatty Liver Disease.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021. Summary drawn from the study's full text. Each statement is followed by the exact sentence it comes from. This is a research summary, not medical advice.

Study type

Double-blind, randomized trial
“92 biomarkers associated with immunity, chemotaxis, and metabolism were measured in plasma samples from 61 PWH with NAFLD who participated in a double-blind, randomized trial of tesamorelin versus placebo for 12 months.”

Subjects

People with human immunodeficiency virus (HIV) and nonalcoholic fatty liver disease (NAFLD)
“This study used proteomics and gene set enrichment analysis to assess effects of a GH releasing hormone (GHRH) analog, tesamorelin, on circulating immune markers and liver tissue in people with human immunodeficiency virus (HIV) (PWH) and nonalcoholic fatty liver disease (NAFLD).”

Sample size

61 participants
“92 biomarkers associated with immunity, chemotaxis, and metabolism were measured in plasma samples from 61 PWH with NAFLD who participated in a double-blind, randomized trial of tesamorelin versus placebo for 12 months.”

Duration

12 months
“92 biomarkers associated with immunity, chemotaxis, and metabolism were measured in plasma samples from 61 PWH with NAFLD who participated in a double-blind, randomized trial of tesamorelin versus placebo for 12 months.”

Reported findings

Tesamorelin decreased interconnected proteins related to cytotoxic T-cell and monocyte activation compared to placebo.
“Tesamorelin, compared to placebo, decreased interconnected proteins related to cytotoxic T-cell and monocyte activation.”
Circulating concentrations of 13 proteins were significantly decreased, with no proteins increased, by tesamorelin.
“Circulating concentrations of 13 proteins were significantly decreased, and no proteins increased, by tesamorelin.”
Liver tissue analysis confirmed a significant end-organ signal of down-regulated immune activation pathways.
“Targeted transcriptomics using liver tissue confirmed a significant end-organ signal of down-regulated immune activation pathways.”

Source: PubMed 33852720 · DOI 10.1093/cid/ciab019 · all study summaries

Subjects

People with human immunodeficiency virus (HIV) and nonalcoholic fatty liver disease (NAFLD)

“This study used proteomics and gene set enrichment analysis to assess effects of a GH releasing hormone (GHRH) analog, tesamorelin, on circulating immune markers and liver tissue in people with human immunodeficiency virus (HIV) (PWH) and nonalcoholic fatty liver disease (NAFLD).”

Reported findings

Tesamorelin decreased interconnected proteins related to cytotoxic T-cell and monocyte activation compared to placebo.

“Tesamorelin, compared to placebo, decreased interconnected proteins related to cytotoxic T-cell and monocyte activation.”

Circulating concentrations of 13 proteins were significantly decreased, with no proteins increased, by tesamorelin.

“Circulating concentrations of 13 proteins were significantly decreased, and no proteins increased, by tesamorelin.”

Liver tissue analysis confirmed a significant end-organ signal of down-regulated immune activation pathways.

“Targeted transcriptomics using liver tissue confirmed a significant end-organ signal of down-regulated immune activation pathways.”